CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to ALPMY

Fidaxomicin oral suspension

Phase 3
Astellas Pharma (ALPMY)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Clostridium Difficile-associated Diarrhea (CDAD)

View Full Landscape
Drug Information

Target Indication

Clostridium Difficile-associated Diarrhea (CDAD)

Clinical Trial

NCT02218372

Last updated: 1/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.